Who Owns Axsome Company?

Who Owns Axsome Therapeutics?

Understanding the ownership of Axsome Therapeutics, Inc. is key to grasping its strategic path and accountability. This biopharmaceutical company focuses on novel therapies for central nervous system (CNS) conditions.

Axsome Therapeutics, founded in January 2012, has grown from a clinical-stage to a commercial-stage company. Its market capitalization as of July 2025 is approximately $4.99 billion, a testament to its expanding presence, partly due to products like Auvelity.

Who owns Axsome Therapeutics, Inc.?

Axsome Therapeutics was established on January 12, 2012, in New York, New York. Its founder, Dr. Herriot Tabuteau, also serves as the company's Chief Executive Officer and Chairman, bringing a background in medicine and investment to guide its mission.

Founding Vision

The company was founded with a clear mission to research, develop, and commercialize innovative pharmaceutical products. Its focus is on addressing central nervous system (CNS) disorders where current treatment options are limited.

Initial Funding

In its early stages, Axsome Therapeutics secured funding through private investment rounds. This initial capital was crucial for establishing its operations and beginning its research endeavors.

Transition to Public Ownership

A significant turning point for Axsome's ownership structure was its Initial Public Offering (IPO). This event marked the company's transition to broader public ownership and access to capital markets.

IPO Details

The company's IPO took place on the NASDAQ exchange in November 2015. Through this offering, Axsome Therapeutics successfully raised approximately $57.5 million in gross proceeds.

Capital for Development

The capital raised from the IPO was vital for advancing the company's clinical pipeline. This funding enabled Axsome to further its drug development programs for CNS disorders.

Early Ownership Structure

While specific details regarding individual equity splits at the company's inception are not publicly disclosed, the IPO fundamentally altered its ownership landscape.

The IPO in November 2015 was a pivotal moment, shifting Axsome Therapeutics from private funding to a publicly traded entity. This move provided the necessary capital to propel its drug development initiatives forward, impacting its overall ownership structure and making its stock available to a wider range of investors. Understanding this early phase is key to grasping the current Axsome ownership and who controls Axsome Therapeutics.

Axsome's Public Debut

Axsome Therapeutics became a publicly traded company following its Initial Public Offering (IPO) in November 2015. This event was a significant step in its journey, allowing for greater capital infusion and broader investor participation.

• Founded: January 12, 2012
• Founder: Dr. Herriot Tabuteau
• IPO Date: November 2015
• Exchange: NASDAQ
• Gross Proceeds from IPO: Approximately $57.5 million
• Primary Focus: CNS disorders

Complete Axsome Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Axsome Therapeutics became a publicly traded entity on November 19, 2015, listing on the NASDAQ Capital Market under the ticker 'AXSM'. The initial public offering priced shares at $9.00, raising approximately $51 million. Subsequent capital raises, such as the June 2023 offering that generated $225.0 million, have significantly influenced its ownership structure and provided capital for its growth initiatives.

The ownership landscape of Axsome Therapeutics has seen substantial evolution since its public debut. As of March 31, 2025, institutional investors collectively held a dominant 70.94% of the company's shares, indicating significant backing from large financial entities. Individual investors, conversely, accounted for approximately 16.48% of the ownership during the same period. This distribution highlights the increasing influence of institutional capital in shaping the company's trajectory and reflects ongoing investor confidence in its development pipeline and commercialization strategies.

Key Institutional Holders of Axsome Stock

Major institutional investors play a crucial role in Axsome's shareholder base. Their holdings are closely watched as indicators of market sentiment and company valuation.

• Vanguard Group Inc. is a significant stakeholder, holding 3,876,942 shares as of Q1 2025.
• BlackRock, Inc. also maintains a substantial position with 3,524,411 shares.
• RTW Investments, LP is another key institutional investor, owning 2,922,729 shares.
• Other notable institutional investors include BVF Inc/IL, FMR LLC, Macquarie Group Ltd, Geode Capital Management, LLC, State Street Corp, and Invesco Ltd.
• These holdings underscore the significant percentage of Axsome owned by institutions, which is approximately 70.94% as of March 2025.

The company's journey, including its initial public offering and subsequent capital infusions, has shaped its current ownership structure. Understanding who owns Axsome provides insight into the company's financial backing and strategic direction. For a deeper dive into the company's history and its foundational stages, readers can refer to the Brief History of Axsome.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The strategic direction and governance of Axsome Therapeutics are overseen by its Board of Directors. As of 2025, the board includes Herriot Tabuteau, MD, who serves as the founder, Chief Executive Officer, and Chairman. Other directors include Roger Jeffs, PhD, Susan Mahony, PhD, MBA, Mark Saad, and Mark Coleman, MD.

Axsome Therapeutics operates under a one-share-one-vote structure for its common stock, meaning each share of common stock grants its holder one vote on matters presented to shareholders. The company's Certificate of Incorporation explicitly prohibits cumulative voting for director elections. While the company has the authority to issue preferred stock, which could potentially alter voting rights and influence control, no preferred stock was outstanding as of December 31, 2019, and there is no public information indicating any issuance since that date. Therefore, control currently resides with the common shareholders. The 2025 Annual Meeting of Stockholders, held virtually on June 6, 2025, addressed key items including the election of a Class I director, the approval of the 2025 Long-Term Incentive Plan, and the ratification of the independent registered public accounting firm. Understanding the Target Market of Axsome is crucial for appreciating the company's strategic decisions.

Understanding Axsome's Voting Power

Axsome Therapeutics employs a straightforward voting structure. Control is primarily vested in common shareholders due to the one-share-one-vote principle.

• Common stock holders have one vote per share.
• Cumulative voting for director elections is not permitted.
• The Board of Directors oversees strategic direction and governance.
• Potential influence from preferred stock exists, but none was outstanding as of late 2019.

Axsome Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent developments have influenced Axsome Therapeutics' ownership landscape. A public offering in June 2023 raised $225.0 million, potentially diluting existing shareholders. While insider holdings saw a slight dip, institutional ownership has remained robust and even increased.

Insider selling, such as Mark Jacobson's sale of over 65,000 shares for more than $6.9 million, contrasts with the growing institutional confidence. This confidence is likely bolstered by the company's strong financial performance, with Q1 2025 net product revenue reaching $121.5 million, a 62% year-over-year increase driven by Auvelity's $96.2 million in sales. Axsome anticipates further growth with upcoming product launches and planned regulatory submissions, believing its current cash reserves will sustain operations until cash flow positivity.

Insider Activity Insights

Insider holdings decreased slightly from March to May 2025. For example, the COO sold a significant portion of his direct holdings, generating substantial proceeds.

Institutional Investor Confidence

Institutional ownership has steadily increased, indicating growing investor confidence. Mutual funds, a key component of this, also saw an upward trend in their holdings.

Financial Performance Drivers

Strong Q1 2025 results show significant year-over-year revenue growth. This performance is primarily attributed to the successful commercialization of key products.

Future Growth Prospects

The company is poised for continued momentum with upcoming product launches and planned regulatory submissions. Axsome believes its financial position supports operations until achieving cash flow positivity, a key milestone for Revenue Streams & Business Model of Axsome.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE